Register for our free email digests:
Products
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Alvogen Fails In Revlimid IPR Attempt
Alvogen’s inter partes review petition challenging a Revlimid patent in the US has been denied by the PTAB, following similar denials of petitions by Dr Reddy’s over three other Revlimid patents.
Saphris Asenapine Ruling Is Bounced Back By US Appeals Court
Canadian Body Welcomes Pharmacare Report
An interim report on implementing national pharmacare in Canada that highlights the importance of cost savings and access to medicines has been welcomed by local off-patent industry body the CGPA.
Biosimilars Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Alvotech Starts European Trial For High-Concentration Adalimumab
UK’s CMA Will Not Take Action Over Remicade Discount Scheme
The UK’s competition regulator will not take action against MSD over a suspected anti-competitive discount scheme for Remicade (infliximab), despite an earlier provisional finding that MSD had a dominant market position and the scheme was in breach of competition law.
Canadian Body Welcomes Pharmacare Report
An interim report on implementing national pharmacare in Canada that highlights the importance of cost savings and access to medicines has been welcomed by local off-patent industry body the CGPA.
Value-Added Medicines Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Accord Agrees Leuprolide Deal as Part of Differentiation Strategy
Celltrion’s Subcutaneous Infliximab Shows Promise
Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.
TLC Seeks A Second Opinion On Doxolipad
After the CHMP last month refused to recommend granting approval for TLC’s doxorubicin hybrid, the firm has asked the committee within the EMA to revisit its opinion.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.